Mannosylated Lipoarabinomannans Inhibit IL-12 Production by Human Dendritic Cells: Evidence for a Negative Signal Delivered Through the Mannose Receptor

Jérôme Nigou, Claudia Zelle-Rieser, Martine Gilleron, Martin Thurnher and Germain Puzo

J Immunol 2001; 166:7477-7485; doi: 10.4049/jimmunol.166.12.7477
http://www.jimmunol.org/content/166/12/7477

References
This article cites 52 articles, 30 of which you can access for free at:
http://www.jimmunol.org/content/166/12/7477.full#ref-list-1

Why The JI? Submit online.
• Rapid Reviews! 30 days* from submission to initial decision
• No Triage! Every submission reviewed by practicing scientists
• Fast Publication! 4 weeks from acceptance to publication

Subscription
Information about subscribing to The Journal of Immunology is online at:
http://jimmunol.org/subscription

Permissions
Submit copyright permission requests at:
http://www.aai.org/About/Publications/JI/copyright.html

Email Alerts
Receive free email-alerts when new articles cite this article. Sign up at:
http://jimmunol.org/alerts
Mannosylated Lipoarabinomannans Inhibit IL-12 Production by Human Dendritic Cells: Evidence for a Negative Signal Delivered Through the Mannose Receptor

Jérôme Nigou,* Claudia Zelle-Rieser,† Martine Gilleron,* Martin Thurnher,† and Germain Puzo2*

IL-12 is a key cytokine in directing the development of type 1 Th cells, which are critical to eradicate intracellular pathogens such as Mycobacterium tuberculosis. Here, we report that mannose-capped lipoarabinomannans (ManLAMs) from Mycobacterium bovis bacillus Calmette-Guérin and Mycobacterium tuberculosis inhibited, in a dose-dependant manner, the LPS-induced IL-12 production by human dendritic cells. The inhibitory activity was abolished by the loss of the mannose caps or the GPI acyl residues. ManLAMs were shown to attenuate TNF-α and IL-12 expression in human mononuclear phagocytes (19). Additionally, ManLAMs were found to bind murine and human macrophages via the mannose receptor (MR; Refs. 20–22), suggesting a role for ManLAMs in the MR-mediated adherence of these mycobacteria to macrophages. However, engagement of the MR, for example, by mannosylated particulate ligands was not sufficient to trigger a bactericidal response in macrophages (23). Furthermore, ManLAMs can effectively induce expression of the antiinflammatory cytokine TGF-β (13). All of these findings suggest that ManLAMs may contribute to the persistence of M. tuberculosis and M. bovis BCG within macrophages.

In the present study, we assessed whether purified ManLAMs from M. bovis BCG and M. tuberculosis were able to inhibit IL-12 production by human dendritic cells (DCs) stimulated with LPS. The relationship between the structure of ManLAM acyl forms and their capacity to inhibit IL-12 production as well as the role of signals transduced by the MR has been examined.

Materials and Methods

Mycobacterial glycoconjugate purification

ManLAMs and mannose-capped arabinomannans (ManAMs) from M. bovis BCG Pasteur strain were purified as described previously (24).

Hydropathic interaction chromatography of ManLAMs

Cellular ManLAMs (cManLAMs; 10 mg) were loaded in 0.1 M ammonium acetate solution containing 15% (v/v) propanol-1 to a octyl-Sepharose CL-4B (Pharmacia, Orsay, France) column (20 x 1.5 cm) preequilibrated with the same buffer. The column was first eluted with 50 ml of equilibration buffer and then with a linear propanol-1 gradient from 15 to 65% (v/v; 250 ml each) in 0.1 M ammonium acetate solution at a flow rate...
of 5 ml/h. The fractions were collected every 15 min. A total of 20 μl of each fraction was dried and submitted to acidic hydrolysis (100 μl of trifluoroacetic acid 2 M, 2 h at 110°C). The hydrolysates were dried, reconstituted in water, and then analyzed by high pH anion exchange chromatography for arabinose and mannose content.

**Preparation of decylated ManLAMs**

Total fraction of ManLAMs (tManLAMs; 200 μg) was incubated in 200 μl of NaOH 0.1 M for 2 h at 37°C. After neutralization with 200 μl of HCl 0.1 M, the reaction products were dialyzed against water.

**Preparation of α-mannosidase-treated ManLAMs (αtManLAMs)**

A total of 200 μg of tManLAMs was incubated for 6 h at 37°C in 30 μl of α-mannosidase solution (Ref. 25) (2 mg/ml, 0.1 M sodium acetate buffer, pH 4.5, 1.5 mM ZnSO₄). After a second addition of 50 μl of enzyme solution, the reaction was performed overnight. The reaction products then were dialyzed against 50 mM NH₄CO₃, pH 7.6. Elimination of α-mannosidase was achieved by denaturation (2 min at 110°C) followed by overnight tryptic digestion (37°C, trypsin/α-mannosidase = 2% by weight). αtManLAMs were recovered after dialysis against water and analyzed for their cap contents by capillary electrophoresis (CE; see below).

**CE and manno oligosaccharide cap quantification**

ManLAMs (30–60 pmol) were submitted to mild acidic hydrolysis (15 μl of HCl 0.1 M for 20 min at 110°C; Ref. 24) in the presence of mannheptose (100 pmol) as internal standard (26). After drying under vacuum, the reaction products were mixed with 0.4 μl of 0.2 M 1-aminopyrene-3,6,8-trisulfonate (APTS; Interchim, Montluçon, France) in 15% acetic acid and 0.4 μl of a 1 M sodium cyanoborohydride solution dissolved in tetrahydrofuran (27). The reaction was performed for 90 min at 55°C and was quenched by addition of 20 μl of water. From 1 to 5 μl of the APTS derivatives solution was dissolved again in 20 μl of total water before injection in CE. Analyses were performed on a P/ACE CE system (Beckman Instruments, Palo Alto, CA) with the cathode on the injection side and the anode on the detection side (reverse polarity). The electropherograms were acquired and stored on a Dell XPS P60 computer with the System Gold software package (Beckman Instruments).

APTS derivatives were loaded by applying 0.5 psi (3.45 kPa) vacuum for 5 s (6.5 ml injected). Separations were performed with an uncoated fused-silica capillary column (Sigma, Division Supelco, Saint-Quentin-Fallavier, France) with a 50-μm internal diameter and a 40-cm effective length (47 cm total length). Analyses were conducted at a temperature of 25°C with an applied voltage of 20 kV and with acetic acid 1% (w/v), triethylamine 30 mM in water, pH 3.5 as running electrolyte. The detection system consisted of a Beckman laser-induced fluorescence (LIF) equipped with a 4-nm argon-ion laser with the excitation wavelength of 488 nm and 5 μM of HCl 0.1 M, the reaction products were dialyzed against water. Wells were washed thoroughly before the addition of a biotinylated anti-IL-12 mAb (500 ng/ml). After 1 h, wells were washed again and then incubated with streptavidin-HRP (1:8000; Zymed Laboratories, San Francisco, CA) for another 60 min. Tetramethylbenzidine (BD PharMingen, San Diego, CA) was used as a substrate, and 2 M H₂SO₄ was used to stop the enzyme reaction. IL-12 p40 was measured with a commercially available kit (Genzyme, Cambridge, MA). IL-12 was quantitated with an automatic plate reader.

The capacity to produce cytokines can differ dramatically between individuals (IL-12 p70 production ranged from 0.2 to 5 ng/ml). Therefore, we decided to present the data as percentage of inhibition. The detection limit of the IL-12 p70 ELISA is 15 pg/ml.

**Results**

**Effect of ManLAMs on IL-12 production by human DCs**

The total fraction of ManLAMs (tManLAMs) was obtained by ethanol/water extraction of the disrupted delipidated cells (16). We first tested the ability of tManLAMs from *M. bovis* BCG to stimulate the production of IL-12 by human monocyte-derived DCs. In addition to abundant MHC molecules, these cells express the MR (Fig. 1). In consistency with previous findings in murine macrophages (15). Next, we tested whether tManLAMs can inhibit IL-12 production by DCs stimulated with 2 ng/ml LPS. Addition of tManLAMs to LPS-stimulated-DCs resulted in a dose-dependent inhibition of IL-12 p70 production with 90% inhibition at 50 μg/ml (around 3 μM) tManLAMs (Fig. 2). The same concentration of tManLAMs induced an inhibition of IL-12 p40 production of ~80% (data not shown).

**Determination of ManLAM domains involved in the inhibition of IL-12 production by DCs**

ManLAMs present a tripartite structure composed of the GPI anchor, the polysaccharide core, and the manno oligosaccharide caps (16, 17). The caps of tManLAMs from *M. bovis* BCG and *M. tuberculosis* are mono-α(1→2)-di-, and α(1→2)-triaminopyranosides, among which the dimannopyranoside is the most abundant motif (24, 26, 28). Their presence and their structure has been evidenced, after mild acidic hydrolysis, APTS derivatization, and analysis by CE-LIF (24, 26).
To determine whether specific tManLAM domains were involved in their inhibitory effect of IL-12 production by DCs, degraded tManLAMs were prepared. tManLAMs were treated with α-exomannosidase to obtain tManLAMs devoid of mannoooligosaccharide caps (αtManLAMs). The reaction was controlled by CE-LIF analysis by using the procedure for cap analysis as described above (24, 26). A typical electropherogram obtained for α-exomannosidase-treated tManLAMs is presented in Fig. 3a. No significant peak corresponding to mannoooligosaccharide caps was detected, revealing that αtManLAMs are actually devoid of mannoooligosaccharide caps. In contrast to native tManLAMs, αtManLAMs at a dose of 10 μg/ml failed to inhibit IL-12 production by DCs (Fig. 3b). Moreover, PILAMs from M. smegmatis containing phosphoinositol caps instead of mannoooligosaccharide caps (14), previously described as inducing IL-12 secretion (15), also were unable to inhibit IL-12 secretion by DCs (Fig. 3b). Taken together, these results indicated that mannoooligosaccharide caps were critical structural features for the IL-12 inhibitory effect of ManLAMs.

To test the role of the lipidic part of the GPI anchor, deacylated tManLAMs (dtManLAMs), were prepared by alkali treatment. In addition, the activity of M. bovis BCG ManAMs, which are distinguished from ManLAMs by the absence of the GPI anchor, was investigated (29). Both dtManLAMs and ManAMs (Fig. 4), at 10 μg/ml, were unable to inhibit IL-12 production, indicating that a native acylated GPI anchor was required for the tManLAM inhibitory effect. In summary, both the mannoooligosaccharide caps and the lipidic moiety of the GPI anchor were the crucial domains mediating the inhibitory activity of tManLAMs on DC IL-12 production.

To determine whether specific tManLAM domains were involved in their inhibitory effect of IL-12 production by DCs, degraded tManLAMs were prepared. tManLAMs were treated with α-exomannosidase to obtain tManLAMs devoid of mannoooligosaccharide caps (αtManLAMs). The reaction was controlled by CE-LIF analysis by using the procedure for cap analysis as described above (24, 26). A typical electropherogram obtained for α-exomannosidase-treated tManLAMs is presented in Fig. 3a. No significant peak corresponding to mannoooligosaccharide caps was detected, revealing that αtManLAMs are actually devoid of mannoooligosaccharide caps. In contrast to native tManLAMs, αtManLAMs at a dose of 10 μg/ml failed to inhibit IL-12 production by DCs (Fig. 3b). Moreover, PILAMs from M. smegmatis containing phosphoinositol caps instead of mannoooligosaccharide caps (14), previously described as inducing IL-12 secretion (15), also were unable to inhibit IL-12 secretion by DCs (Fig. 3b). Taken together, these results indicated that mannoooligosaccharide caps were critical structural features for the IL-12 inhibitory effect of ManLAMs.

To test the role of the lipidic part of the GPI anchor, deacylated tManLAMs (dtManLAMs), were prepared by alkali treatment. In addition, the activity of M. bovis BCG ManAMs, which are distinguished from ManLAMs by the absence of the GPI anchor, was investigated (29). Both dtManLAMs and ManAMs (Fig. 4), at 10 μg/ml, were unable to inhibit IL-12 production, indicating that a native acylated GPI anchor was required for the tManLAM inhibitory effect. In summary, both the mannoooligosaccharide caps and the lipidic moiety of the GPI anchor were the crucial domains mediating the inhibitory activity of tManLAMs on DC IL-12 production.

FIGURE 1. Phenotype of DCs. DCs were differentiated from monocytes as described in Materials and Methods. Day 5 DCs were recultured in the absence (bold lines) or presence of LPS (2 ng/ml; normal lines) for 48 h and analyzed by flow cytometry for the surface expression of the indicated Ags.

FIGURE 2. M. bovis BCG tManLAMs inhibit IL-12 production by DCs stimulated with LPS. DCs (3 x 10^5/ml) were incubated with 2 ng/ml LPS and different amounts of tManLAMs. Supernatants were harvested for IL-12 p70 assays after 48 h. The capacity to produce cytokines can differ dramatically between individuals (IL-12 production ranged from 0.2 to 5 ng/ml). Therefore, the data will be presented along the present study as percentage of inhibition. The detection limit of the IL-12 p70 ELISA was 15 pg/ml. tManLAMs, total pool of ManLAMs.

FIGURE 3. LAMs without mannoooligosaccharide caps are unable to inhibit IL-12 production by DCs. a, CE-LIF analysis of mannoooligosaccharide caps from tManLAMs (top) and αtManLAMs (bottom). One microgram of tManLAMs or αtManLAMs were hydrolyzed with 15 μl of HCl 0.1 M for 20 min at 110°C, dried, APTS derivatized, and submitted to CE migration. CE analysis was conducted with a 470 mm x 50 mm capillary, at a temperature of 25°C with an applied voltage of ~20 kV and monitored by LIF. Acetic acid 1% (w/v), triethylamine 30 mM in water pH 3.5 was used as running electrolyte. A, Ara-APTS; S, mannoheptose-APTS, internal standard; AA, Araf-Ara-APTS; AM, Manp-Ara-APTS; AMM, Manp-Manp-Ara-APTS; AMMM, Manp-Manp-Manp-Ara-APTS. AM, AMM and AMMM arise from mono-, di-, and trimannoside caps, respectively. b, IL-12 p70 production by LPS-stimulated DCs in the presence of tManLAMs, αtManLAMs, or M. smegmatis PILAMs. DCs (3 x 10^5/ml) were incubated with 2 ng/ml LPS and 10 μg/ml tManLAMs, αtManLAMs, or M. smegmatis PILAM. Supernatants were harvested for IL-12 p70 assays after 48 h. /, LPS (2 ng/ml) alone.
In previous studies, we have reported that the M. bovis BCG tManLAMs can be subdivided into a parietal pool and a cellular pool (pManLAMs and cManLAMs, respectively) based on their extraction mode (24, 30). It is noteworthy that the amount of cManLAMs represents >90% of tManLAMs. M. bovis BCG pManLAMs and cManLAMs mainly differ by the structure of the GPI anchor (24). pManLAMs contain a single acyl form bearing one nonconventional acyl group on the glycerol unit tentatively assigned to 12-O-methoxypropanoyl-12-hydroxystearic acid (24). Contrarily, cManLAMs are characterized by four multiacylated acyl forms, bearing at least one fatty acid for the less acylated form and at least three fatty acids for the most acylated form (31). These acyl groups are mainly palmitic and tuberculostearic acids and are located on the glycerol and the myo-inositol units (24, 31). Nevertheless, an additional acyl residue can be found on the mannosyl unit linked on O-2 of the myo-inositol (32). We then tested the ability of pManLAMs and cManLAMs to inhibit IL-12 production by DCs. Only cManLAMs were able to inhibit IL-12 production by DCs, suggesting that the acylation state influences the inhibitory activity of ManLAMs. To test this hypothesis, we tentatively fractionated the different cManLAM acyl forms by hydrophobic interaction chromatography.

Fractionation and identification of M. bovis BCG cManLAM acyl forms

cManLAMs were loaded on an octyl-Sepharose column and eluted with an increasing gradient of propanol-1 in ammonium acetate 0.1 M in water. The elution profile (Fig. 5b) showed four peaks, two of weak intensity, peaks A and B, eluting at ~27 and 28% propanol-1 respectively, and two of higher intensity, peaks C and D, eluting at ~31 and 35% propanol-1 respectively. The fractions corresponding to the different peaks were pooled, dialyzed, dried, and analyzed by one-dimensional $^{31}$P NMR in DMSO (31). One-dimensional $^{31}$P spectrum of cManLAMs from peak D (Fig. 5d) exhibited a single resonance at δ 1.66 corresponding to phosphate P1 previously evidenced in the cManLAM mixture (Fig. 5e; Ref. 31). Likewise, one-dimensional $^{31}$P spectrum of ManLAMs from peak C (Fig. 5c) exhibited a single resonance at δ 1.83 corresponding to phosphate P3. As previously established by two-dimensional $^{1}H-^{31}$P NMR experiments, P1 and P3 typify ManLAM acyl forms containing at least three (two on the glycerol and one on O-3 of the myo-inositol) and two fatty acyl groups (both on the glycerol), respectively (see Fig. 6d, NMR data only). Unfortunately, the amount of cManLAMs collected in fractions A and B were not enough to record a one-dimensional $^{31}$P NMR spectrum with significant $^{31}$P signal. However, from the one-dimensional $^{31}$P spectrum of the cManLAMs (Fig. 5a), it can be proposed that cManLAM A and B correspond to the remaining P5 and P4 phosphates. As noticed above for P1 and P3, we have previously established that cManLAMs characterized by P4 and P5 contain at least two and one fatty acids, respectively (see Fig. 6d, NMR data only). So, from the elution order of ManLAM A and B, it can be
advanced that they correspond to the at least monoacylated (P5) and diacylated (P4) forms, respectively.

Structural characterization of *M. bovis* BCG ManLAM acyl forms

A supplementary acylation site, on position 6 of the mannopyranose (Manp) unit linked to the O-2 of the myo-inositol, has been reported previously for *M. tuberculosis* ManLAMs (32). This data was established by degradative methods applied on the total ManLAM pool. Unfortunately, our $^{31}$P NMR approach did not allow us to define the acylation state of this Manp unit (see Fig. 6d). To tentatively gain access to this information, the four cManLAM acyl forms were analyzed by matrix-assisted laser desorption-ionization (MALDI)/MS (not shown). The mass spectra obtained were similar, all showing a broad peak centered around 17 kDa with a heterogeneity estimated at 5–6 kDa. This resulted from the large ManLAM molecular heterogeneity attributable to the presence of many glyco forms. As a consequence, MALDI/MS analysis was unsuccessful in determining precisely the presence of a supplementary acyl group on the purified

![Graph showing quantification of fatty acids](http://www.jimmunol.org/)

![Graph showing caps distribution](http://www.jimmunol.org/)

![Mannooligosaccharide caps](http://www.jimmunol.org/)

### Table 1

<table>
<thead>
<tr>
<th>Acyl-forms</th>
<th>R$_1$</th>
<th>R$_2$</th>
<th>R$_3$</th>
<th>R$_4$</th>
</tr>
</thead>
<tbody>
<tr>
<td>pManLAMs</td>
<td>NMR$^a$</td>
<td>GC$^b$</td>
<td>NMR$^a$</td>
<td>GC$^b$</td>
</tr>
<tr>
<td>cManLAMs</td>
<td>+ C18-OR</td>
<td>-</td>
<td>+ C19</td>
<td>+ C16</td>
</tr>
<tr>
<td>D</td>
<td>P1</td>
<td>+ C19</td>
<td>+ C16</td>
<td>-</td>
</tr>
<tr>
<td>C</td>
<td>P3</td>
<td>+ C19</td>
<td>+ C16</td>
<td>-</td>
</tr>
<tr>
<td>B</td>
<td>P4</td>
<td>+ C16</td>
<td>-</td>
<td>/</td>
</tr>
<tr>
<td>A</td>
<td>P5</td>
<td>+ C16</td>
<td>-</td>
<td>/</td>
</tr>
</tbody>
</table>

$^a$ from (31); $^b$ from the data in the present study and (24).
ManLAMs inhibit IL-12 production via MR ligation

**Discussion**

IL-12 is a dominant factor in directing the development of Th1 cells, which produce high levels of IFN-γ (1). Th1 cells together with cytolytic CD8 T cells are critical to eradicate intracellular pathogens such as *M. tuberculosis* (36, 37). Indeed, in humans, IL-12 deficiency leads to a predisposition to mycobacterial infections despite the formation of mature granulomas (3). Surprisingly, *M. tuberculosis*, the causative agent of human tuberculosis, induces IL-12 production in vitro from murine phagocytic cells (38) and human DCs (39) and in vivo at the human infection site (40). The *M. tuberculosis* 19-kDa lipoprotein was found to be the potent stimulator of TLR-2-dependent IL-12 production by human macrophages (41). However, in vivo, administration of IL-12 to mice enhances their resistance to *M. tuberculosis* infection, suggesting that the level of IL-12 is critical to the control of *M. tuberculosis* infection (42, 43).
In the present study, we demonstrate that *M. bovis* BCG ManLAMs inhibit IL-12 production in human monocyte-derived DCs, most likely via MR ligation. This property also was shared by *M. tuberculosis* H37Rv ManLAMs (not shown). In contrast, PILAMs from *M. smegmatis*, a nonpathogenic mycobacterial strain, did not inhibit the production of IL-12. ManLAMs and PILAMs share the same tripartite structure composed of the polysaccharidic core, the GPI anchor, and the caps (16, 17). To date, the cap structure, assigned to mannooligosaccharide and phospho-myo-inositol residues, typify ManLAMs and PILAMs, respectively. Thus, mannooligosaccharide caps appear to play a critical role in the ability of *M. bovis* BCG and *M. tuberculosis* tManLAMs to inhibit IL-12 production by DCs. This assumption was further supported by the finding that *M. bovis* BCG uncapped tManLAMs, obtained by an α-mannosidase treatment, failed to inhibit IL-12 production. The acyl groups of the GPI anchor appear to play a crucial role because: 1) *M. bovis* BCG tManLAM deacylation abolished IL-12 inhibitory effect; 2) this activity was restored after reacetylation by palmitic anhydride; 3) *M. bovis* BCG ManAMs, corresponding to ManLAMs devoid of the GPI anchor (29), failed to inhibit IL-12 production; and finally, 4) *M. bovis* BCG pManLAMs were found to be devoid of inhibitory activity. It is noteworthy that dtManLAMs as well as pManLAMs and ManAMs contained the same caps and in similar number as tManLAMs (Fig. 6b). The abundance of pManLAM acyl form in the BCG envelope represent only less than 10% of tManLAMs (24). This is in agreement with the fact that *M. bovis* BCG tManLAMs inhibited IL-12 production. *M. bovis* BCG pManLAMs (24) differ from *M. bovis* BCG cManLAM acyl forms (29) and from *M. tuberculosis* H37Rv ManLAM acyl forms (28) by the GPI anchor bearing a single acyl group tentatively assigned to 12-O-methoxypropanoyl-12-hydroxystearic acid (Ref. 24; Fig. 6d). Collectively, these findings suggested that GPI acyl group structure and GPI acylation degree modulate ManLAM activity. We previously have established, based on one-dimensional $^{31}$P and two-dimensional $^1$H-$^{31}$P NMR experiments, that *M. bovis* BCG cManLAMs are composed by a mixture of four acyl forms, namely A (at least one acyl group, on the glycerol), B (at least two acyl groups, one on the glycerol and the second one on O-3 of the myo-inositol unit), C (also at least two acyl groups but both on glycerol), and D (at least three acyl groups, two on glycerol and one on O-3 of the myo-inositol unit; Ref. 31; Fig. 6d). In this report, the four *M. bovis* BCG cManLAM acyl forms A, B, C, and D were successfully fractionated by hydrophobic interaction chromatography and their structure characterized by the chemical shift of the $^{31}$P resonance. In addition to the three acylation sites accessible by our $^{31}$P NMR experiments, another potential position has been described in *M. tuberculosis* ManLAMs, by Brennan and coworkers (32), on the O-6 of the mannosyl unit linked on O-2 of the myo-inositol. Despite the use of nondegradative techniques, such as NMR or MALDI/MS, our efforts to determine the presence of a supplementary fatty acid on the purified cManLAM acyl forms were not successful. As a consequence, this structural information was assessed, with less accuracy, by fatty acid quantification by GC analysis after alkaline hydrolysis. Palmitic and tuberculostearic acids were the major fatty acids liberated, but stearic acid also was recovered in small amount (Fig. 6a). The determination of the total number of fatty acids per ManLAM molecule allowed us to propose the final structures for the cManLAM acyl forms A, B, C, and D as presented in Fig. 6d. The four purified BCG cManLAM acyl forms A, B, C, and D, at a concentration of 10 μg/ml, exhibited the same IL-12 inhibitory effect as tManLAMs. The dominant acyl...
ManLAMs and ManLAMs have been shown to elicit TGF-β production (46). However, complement receptor type 3 (CR3, CD11b/CD18) of human monocytes is envisaged for the inhibition of IL-12 production in response to fatty acid on the GPI mannosyl unit (Fig. 6). Thus, ManLAM clustering seems to require at least two fatty acyl appendages on the GPI (assumption corroborated by S. Sidobre, G. Puzo, and M. Rivière, unpublished results), and the inhibitory effect of ManLAMs is attributable to differential clustering capacities. An efficient cManLAM clustering would allow mannooligosaccharide caps from different cManLAM molecules to bind the MR via multiple CRDs resulting in high-affinity binding, or more precisely, in high-avidity binding. In contrast, M. bovis BCG pManLAMs, containing a single-branched fatty acid, might not cluster, leading to low-affinity binding to the MR (Fig. 9). Indeed, pManLAMs and cManLAMs acyl forms have the same mannooligosaccharide caps and in similar number per molecule, suggesting that the cap structure was not responsible for the differences in biological activity. Moreover, differences in binding affinity between M. bovis BCG pManLAMs and cManLAMs to C-type lectins have recently been established by Sidobre et al. (25). Indeed, M. bovis BCG pManLAMs were found to bind to the human surfactant protein A with a higher affinity than M. bovis BCG pManLAMs (25). Surfactant protein A is a C-type lectin containing 18 CRD with the same carbohydrate recognition specificity as the MR (45). From these data, it can be concluded that the ManLAM capacity to inhibit IL-12 production by DCs is controlled by the binding affinity to the MR and, consequently, by their capacity to cluster, i.e., to form large aggregates in water. The capacity of ManLAMs to form aggregates is evidenced by the line width of their $^{31}$P NMR resonance in water. Indeed, in contrast to M. bovis BCG cManLAMs typified by a large $^{31}$P resonance, pManLAMs and dtManLAMs show well resolved signals indicating that these compounds are poorly aggregated in water (Ref. 24; Fig. 9). Thus, ManLAM clustering seems to require at least two fatty acyl appendages on the GPI (assumption corroborated by S. Sidobre, G. Puzo, and M. Rivière, unpublished results), and the inhibitory effect of cManLAM acyl form A can be explained by the presence of an extra fatty acid on the GPI mannosyl unit (Fig. 6, a and d).

Mechanisms other than the binding to the MR also could be envisaged for the inhibition of IL-12 production in response to ManLAMs. Indeed, it has been established that the binding to the complement receptor type 3 (CR3, CD11b/CD18) of human monocytes suppresses IL-12 production (46). However, $\beta$-glucans but not the $\alpha$-mannans are able to bind CR3, via a cation-independent lectin site (47), suggesting that CR3 does not mediate ManLAM IL-12 inhibitory effect. The ManLAM effect also could result from a negative regulation of IL-12 synthesis by the production of anti-inflammatory cytokines such as IL-10 and TGF-β. However, PILAMs and ManLAMs have been shown to elicit TGF-β in similar amount from human monocytes, whereas PILAMs are more potent inducers of IL-10 than ManLAMs (13).

Therefore, we favor the hypothesis that the inhibition of IL-12 production by DCs in response to ManLAMs is mediated by the MR. The mechanism by which the MR signaling antagonizes CD14/TLR signaling remains an interesting question. In all systems where IL-12 suppression has been molecularly defined, it was found predominantly at the transcriptional level (7). In fact, IL-12 inhibition mediated by MR appears to be able to proceed by more than one mechanism. As noticed above, the signaling pathway of IL-12 stimulation by LPS and PILAMs (8) requires TLR-4 and TLR-2 respectively. TLRs activate intracellular signaling, most notably via the transcription factor NF-κB, which results in the induction of genes coding for effectors of innate immunity such as TNF-α and chemokines (48). The signaling pathway requires the MyD88 adaptor proteins that interact with the cytoplasmic domain of TLR and recruits IL-1R-associated serine/threonine kinase (49, 50). At present, it is unclear how ManLAMs can interfere with this signaling pathway through MR ligation. ManLAMs were found to alter signaling pathway activation of human mononuclear phagocytes by promoting the tyrosine phosphatase 1 (SHP-1), a tyrosine phosphatase known to be important for attenuating activation signals (19). It is conceivable that ManLAMs exert their inhibitory effects by inducing the dephosphorylation of multiple proteins, including mitogen-activated protein kinase, involved in the IL-12 signaling pathway. It also has been reported that ManLAMs induced nuclear translocation of the transcription factor KBF-1 in murine macrophages (51). KBF-1 is a homodimer of the NF-κB subunit protein p50 that can function as a transcriptional repressor by blocking the binding of the NF-κB p50-p65 heterodimer to DNA (52) and consequently the production of IL-12. Finally, MR also serves as a signaling receptor to elicit transient rise in intracellular free Ca$^{2+}$ concentration in macrophages by a mechanism requiring coligation of both CD14 and MR (53). Consequently, ManLAM binding to MR and ligation to CD14 could prevent TLR signaling.

In summary, the present study provides support that ManLAMs are virulence factors that contribute to the persistence of M. bovis BCG and M. tuberculosis in the host and to their maintenance in the human reservoir. This study highlights that the inhibition of IL-12 production by DCs is modulated by the structure of the ManLAM acyl forms. Thus, structural modifications of ManLAM GPI anchor may represent a mechanism for mycobacteria to gain advantage within host tissues.

The activation of macrophages and DCs depends on the net balance between positive and negative signals. Although it is established that the CD14/TLR pathway activates macrophages and DCs, the present study demonstrates that MR ligation negatively regulates DC function and that the MR can transduce inhibitory signals that interfere with TLR-mediated stimulatory signals.

**Acknowledgments**

We gratefully acknowledge Thérèse Brando for technical assistance with CE-LIF and Drs. Stéphane Sidobre and Michel Rivière for stimulating discussions.

**References**


275:2415.


7485The Journal of Immunology


